… This study concluded that cytotoxic chemotherapy, more specifically docetaxel with prednisone,
can significantly prolong OS in men with mCRPC and was the basis of the United States …

… prostate cancer are the result of metastatic castration-refractory (CR) disease. Docetaxel
was the first agent to offer survival advantage in patients with metastatic CR prostate cancer (…

… ) 99-16 clinical trials established docetaxel-based chemotherapy as preferred first-line …
-resistant prostate cancer (mCRPC). However, only about half receive benefit from docetaxel, and …

… with chemotherapy-naive castrate-resistant prostate cancer who had received docetaxel 45
mg/m … Treatment was held when the patients had reached a >50% prostate-specific antigen …

… prostate cancer also benefit from docetaxel administration, expanding the role of chemotherapy
in the prostate cancer … for post-docetaxel metastatic castration-resistant prostate cancer. …

… plus carboplatin in patients with castration-resistant prostate cancer who have progressed
after response to prior docetaxel chemotherapy: The RECARDO trial - ScienceDirect …

… with CRPC previously treated with docetaxel. … cancer prostate at the Institut Gustave Roussy
were administered subsequent docetaxel after front-line docetaxel-based chemotherapy. …

… In 2004, two large, randomized, phase II trials showed that docetaxel-based chemotherapy
… -resistant prostate cancer (CRPC) [1,2]. These studies changed the goal of chemotherapy …

… prostate cancer, which leads to remissions typically lasting 2 to 3 years, but in most men
prostate cancer … -independent prostate cancer patients utilizing docetaxel chemotherapy, setting …

… TTP on docetaxel and shorter … docetaxel chemotherapy were observed in this subset of
pts. Since they have lower probability of response to second-line endocrine therapy, docetaxel …